Objectives: There is no licensed, dose-appropriate formulation of hydrocortisone for children with adrenal insufficiency (AI) and patients rely on compounded adult medication. The aim of this study was to evaluate the absorption, palatability and safety of Infacort ® , an immediate-release, granule formulation of hydrocortisone with taste masking.
doses as low as 0.5 mg required for neonates and infants. 9 A hydrocortisone suspension was available in the USA but is no longer marketed as it was not bioequivalent to tablets. 10 There is therefore an unmet need to develop a licensed paediatric formulation of hydrocortisone specifically designed for the treatment of children with AI and CAH.
Paediatric patients have specific requirements for drug formulation that include an appropriate dosing route, improved palatability, ease of administration for caregivers, dosing flexibility and stability. Infacort A Phase 1 study of Infacort ® demonstrated good tolerability and palatability and bioequivalence to licensed hydrocortisone tablets in healthy volunteers. 9 Undertaking clinical trials in neonates, infants and children is challenging for practical and ethical reasons and for this reason off-label use accounts for up to 60% of medicines administered to children in Europe and the United States. 11, 12 To date, there have only been two medications licensed in Europe through the EMA Paediatric
Use Marketing Authorisation (PUMA) route. To support a PUMA, and as part of a larger European Commission funded project to improve therapy for children with adrenal insufficiency (http://www.tain-project.org/), we undertook a study in neonates, infants and children aged <6 years with AI, designed to evaluate the absorption, palatability and safety of Infacort ® .
| SUBJECTS AND METHODS

| Trial design
This was a Phase 3, open-label, single-dose study conducted at a single centre; Charité-Universitätsmedizin, Berlin, Germany. The study enrolled subjects into three consecutive cohorts: Cohort 1, children (aged 2 to <6 years, n = 12); Cohort 2, infants (aged 28 days to <2 years, n = 6); and Cohort 3, neonates (aged 1 to <28 days, n = 6).
Neonatal participants were also recruited at remote sites but had their care transferred to the central site for the duration of the study through a "flying" doctor concept whereby central-site staff visited remote sites to perform study assessments. 
| Ethics
| Study population
Comprised adequately hydrated and nourished children (male or female) aged <6 years diagnosed with AI (confirmed by an inappropriately low cortisol level) who were currently receiving hydrocortisone with or without fludrocortisone. Children were excluded from the study if they: were experiencing a current adrenal crisis;
had clinical signs of acute infection or fever on Day 1; were unable to take oral medications; were receiving concomitant therapy (other than for AI, vitamin D, fluoride, thyroxine and growth hormone, which were permitted); had a parent/carer who could not understand or give written consent or were unwilling to consent to the saving and propagation of pseudonymized medical data in this study ( Table 1) . Table S1 ); the dose was poured directly onto the subject's tongue or on a spoon and administered as dry granules followed by a drink of water or breastmilk in newborns. As food has been noted to delay hydrocortisone absorption and prolong response, 13 
| Treatment
| End-points
The primary end-point of this study was maximum serum cortisol concentration up to 240 minutes after Infacort ® administration using samples taken at 0, 60 and 240 minutes postdose. Secondary end-points included palatability of Infacort ® , AEs and vital signs recorded during the study. Clinical or laboratory events related to a lack of absorption of hydrocortisone from Infacort ® were considered as demonstrating a lack of efficacy and were therefore not recorded as AEs.
| Assessments
During Visit 2, all study cohorts had blood samples taken at base- were queried about the palatability of Infacort ® after administration using an adjusted 5-item Likert questionnaire (see Table S1 ).
| Statistical methods
Pharmacokinetic (PK) data from two Phase 1 studies (ClinicalTrials.
healthy adult volunteers 9 were used to derive and minimize the population size in the current study and, as a result, this study aimed to enrol 24 subjects as this provided >90% power (alpha 1%) to demonstrate that cortisol levels were higher than baseline after administration of Infacort ® . The safety population comprised all subjects who received one complete or partial dose of Infacort ® . The PK population included all subjects in the safety population for whom there was an adequate set of data to derive the maximum serum concentration (C max ) of cortisol without any major PK-related protocol violations (eg incomplete Infacort ® intake or vomiting). All cortisol absorption analyses (primary and secondary) were performed based on the PK population, using data determined by the central laboratory. Safety analyses were conducted in the safety population; no formal statistical testing was performed for safety end-points. All variables were presented by cohort and overall. The hypothesis that cortisol C max up to 240 minutes after Infacort ® administration was higher than at baseline was tested using a sign test with a significance level of 1%. This statistical analysis was repeated based on cortisol levels at 60 and 240 minutes after Infacort ® administration. A 95% confidence interval (CI) for the ratio of maximum cortisol levels versus baseline cortisol levels was presented using a paired t test for log concentration data. Confidence limits based on the log data were back-transformed to provide a CI for the ratio. The same approach was used to calculate 95% CIs for the ratio of cortisol levels at 60 and 240 minutes after Infacort ® administration vs baseline. Cortisol levels were also categorized using the following groups: <50 nmol L . No adjustments for covariates were performed in this study.
| RESULTS
| Study population characteristics
Demographic and other baseline characteristics for the study subjects are shown in Table 1 . In total, 24 children were enrolled in the study: with CAH, 1 child with hypopituitarism, 2 girls, 4 boys; Cohort 3, 6 neonates with CAH, 4 girls, 2 boys. One neonate was from the Charité site, and 5 were from satellite sites treated by a "flying" investigator team.
Median participant age was 3 years and 3 months and 54.2% were male; all subjects were white. All subjects were successfully dosed.
| Hydrocortisone absorption
The primary end-point of the study was met as shown in Figure 2 .
Increases from baseline in cortisol C max up to 240 minutes after Infacort ® administration were statistically significant for the combined study cohorts (P < .0001). A relevant increase from baseline in cortisol C max was observed in all patients from all three cohorts. The cortisol ). A summary of the primary efficacy analysis across all study cohorts and the geometric mean serum cortisol concentrations at baseline and after Infacort ® administration is shown in P < .0001) and for each cohort (P < .0001, P = .0007 and P < .0001 for Cohorts 1, 2 and 3, respectively). (Table 3) , with ≥50% subjects reporting that the taste, feel in mouth and ease of swallowing were very good and that they were likely to take the medicine again. In addition, 4 of 7 subjects stated that the smell of Infacort ® was neutral.
| Safety
There was no significant spillage of granules, and all subjects were successfully dosed (Table 4) 
| DISCUSSION
This study examined adrenal replacement therapy in a preschool population using a formulation specifically designed for neonates, infants and children. Infacort , which is equivalent to the median daily cortisol level in adults 15 and physiological cortisol levels in adult and paediatric patients are similar. 14 All of the children who completed the children's questionnaire felt Infacort ® tasted good or not bad and parents and carers felt it was better than their child's current medication.
There was no comparator hydrocortisone preparation in this study as there is no licensed dose-appropriate preparation of hydrocortisone, and there is neither a standard method for compounding hydrocortisone nor for administering compounded hydrocortisone. Furthermore, the results of such a study would not be possible to extrapolate to another compounding pharmacy. However, Infacort ® given at a dose of 10 mg to adults is bioequivalent to 10 mg hydrocortisone tablets. 9 The purpose of this study was to demonstrate absorption of Infacort ® in young children, and the 60-minute sample time was chosen as this is the approximate time for the C max after hydrocortisone in children and adults. 9, 16 There has been no study to date on the pharmacokinetics of hydrocortisone in children under the age of 6 years. However, the ) and median (ranges) at: b n = 23, one subject had no results at 240 minutes. c Below limit of quantification (BLQ) was set to lower limit of quantification (LLQ) for baseline samples and zero for postbaseline samples.
Significance of levels above baseline: *P = .0005; **P = .0313; ***P < .0001; ****P = .0026. . 9 These results also reflect the previous reports of cortisol levels during hydrocortisone replacement in paediatrics. 17 In 20 children on twice or thrice daily hydrocortisone replacement regimens, children on both regimes experienced high peak cortisol concentrations followed by periods of hypocortisolaemia. However, these periods of hypocortisolaemia did not correlate with fatigue or reduced levels of activity. 17 In children aged 6-20 years studied after their standard morning dose of hydrocortisone, the mean (range) time to a cortisol <100 nmol L −1 was 289 (140-540) minutes. 16 Variability in cortisol levels after oral hydrocortisone administration has been reported and suggested to be due to variability in clearance between patients. 16, 18 The variability in cortisol levels between the cohorts is additionally explained by the higher dose of hydrocortisone per BSA in the neonatal group (cohort 3) who in some centres are dosed with a quarter of a 10 mg tablet as there is no dose-appropriate paediatric formulation.
Further studies are now needed to determine the optimum replacement regime in childhood using a therapy such as Infacort ® which is available in a dose-appropriate form designed for children.
Drug dosing in neonates is challenging due to significant differences in drug absorption, distribution, metabolism and elimination compared to older children and adults. Most drugs given to neonates are insufficiently studied. 19 Neonates are extremely vulnerable to medication errors. 20 Variability in response to oral dosing has been seen in neonates with other oral medications such as phenobarbital, 21 methadone 22 and digoxin. 23 The palatability questionnaire was a parent-reported measure, so may not completely reflect the child's experience. However, parentreported outcome measures have been correlated with clinical outcomes in some childhood illnesses and are standard of care where children are unable to participate. 24 It was reassuring that in the oldest children who could complete the form, the parents' and children's perceptions of Infacort ® seemed similar. Tolerability of Infacort ® in children under the age of 6 years was similar to that of adults where the majority considered it either good or neutral. 9 This is important as compounded hydrocortisone is often mixed with a sweetener, following methods used worldwide, such as Ora-sweet ® (Perrigo Company, Allegan, Michigan, USA), which contains sucrose, and so could have led to a nonsweet formulation being poorly received. 25, 26 Sweetening of paediatric formulations in this way, to improve palatability, goes against current recommendations for developing licensed products and raises concerns about accidental ingestion and poisoning in children (Guideline on pharmaceutical development of medicines for paediatric use EMA/CHMP/QWP/805880/2012 Rev.
2). The palatability questionnaire was answered after the first exposure to Infacort ® and during the study visit; therefore, it does not reflect continuous daily experience with the drug.
This study highlights the challenges in developing medications for neonates, infants and children and demonstrates that with careful consideration these can be overcome. To address concerns regarding testing in neonates, we used three cohorts of descending age only progressing to test neonates in Cohort 3 after safety had been established in the older cohorts and safety confirmed by an Independent T A B L E 4 Summary of TEAEs and by system organ class and preferred term Data Monitoring Committee. Recruiting neonates to a clinical trial is a major challenge as recruitment, consent and the study needed to be completed within the first 28 days of life. To address this, we agreed with the ethics committee that there would be a single centre and that the team would travel ("fly") to any site where a neonate with AI/CAH was born and administer the trial as from the single site. Germany has a well-established neonatal screening programme with the advantage that clinicians identified neonates shortly after birth. This approach was successful, and 5 of the 6 neonates were recruited from sites outside of the central site.
Limitations in this study include the small number of subjects and the number of samples. However, the investigators and ethics committee were keen that the study should be undertaken as close to routine standard of care as possible, and not include excess samplings. As all children born with AI are reviewed frequently with blood sampling it was possible to avoid extra visits and extra cannulation. The palatability questionnaire was given to every parent/carer and to every child over 3 years of age. The questionnaire was not completed in 5 of 12
children of the first cohort as they were <3 years and/or would not be expected to understand the questionnaire. Assessment of palatability in the very young is challenging but could be undertaken in older children in future studies.
